Core Viewpoint - Jianyou Co., Ltd. announced that it will not adjust the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock prices falling below 90% of the conversion price for 15 out of 30 trading days [2] Group 1 - As of December 12, 2025, Jianyou Co., Ltd. has experienced a situation where the closing price of its stock has been below 90% of the current conversion price for 15 trading days [2] - The company's board of directors decided not to proceed with a downward adjustment of the conversion price at this time [2] - The company has set a future period of four months, from December 13, 2025, to April 12, 2026, during which it will also not propose a downward adjustment if the clause is triggered again [2]

| 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、可转债基本情况 的《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的公告》（公 告编号：2020-061）。 2、公司于2020年7月23日起因实施2019年年度利润分配方案，"健友转债"的 转股价格由54.96元/股调整为42.05元/股。具体内容详见公司2020年7月17日披露的 《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的提示性公告》 （公告编号：2020-070）。 3、公司于2021年6月25日起因实施2021年限制性股票激励计划，"健友转债" 的转股价格由42.05元/股调整为42.01元/股。具体内容详见公司2021年6月24日披露 的《南京健友生化制药股份有 ...

| 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、可转债基本情况 经中国证券监督管理委员会"证监许可［2020］603号"文核准，南京健友生 化制药股份有限公司于2020年4月23日公开发行了5,031,900张可转换公司债券（以 下简称"可转债"），每张面值100元，发行总额50,319.00万元，期限为6年。 经上海证券交易所自律监管决定书［2020］134号文同意，公司50,319.00万元 可转换公司债券于2020年5月22日起在上海证券交易所挂牌交易，债券简称"健友 转债"，债券代码"113579"。 根据《上海证券交易所股票上市规则》等相关规定及《南京健友生化制药股份 有限公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》 ...

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., issued 5,031,900 convertible bonds with a total amount of RMB 503.19 million, which are set to mature on April 22, 2026 [1] - The initial conversion price of the convertible bonds was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing it down to RMB 24.54 per share as of July 7, 2023 [2] - The company’s board has the authority to propose a downward adjustment of the conversion price if the stock price falls below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [3] Group 2 - The company decided not to adjust the conversion price of the convertible bonds during the upcoming six months, even if the conditions for adjustment are met [4] - If the stock price continues to fall and triggers the adjustment conditions after November 24, 2025, the board will reconvene to decide on the potential adjustment [5]

Core Viewpoint - The company has provided updates regarding the FDA approval status of three insulin products developed in collaboration with Tonghua Dongbao, indicating that the approval timeline is subject to change and will be communicated through official announcements [1] Group 1: FDA Approval Status - The company has submitted the application for Aspart Insulin (门冬胰岛素) to the FDA and will announce the approval status promptly if granted [1] - The company anticipates submitting the application for Lispro Insulin (赖脯胰岛素) in 2027 and for Glargine Insulin (甘精胰岛素) in 2026, with these timelines being estimates [1]

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-090 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"预计满足 转股价格修正条款的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简称"公司"）公开发行了 5,031,900 张可转换公司债券 （以下简称"可转债"或"健友转债"），每张面值人民币 100 元，发行总额人 民币 5.0319 亿元，本次可转债存续期限为发行之日起六年，即自 2020 年 4 月 23 日至 2026 年 4 月 22 日。 经上海证券交易所自律监管决定书[2020]134 号文同意，公司 5.0319 亿元 可转债于 2020 年 5 月 22 日起在上海证券 ...

Core Viewpoint - The company has submitted its drug, Glatiramer, for FDA approval and investors are encouraged to monitor future announcements for updates [1] Group 1 - The company confirmed the submission of Glatiramer for FDA approval on December 5 [1] - Investors are advised to pay attention to the company's future announcements regarding the progress of the FDA approval [1]

Core Viewpoint - The company is nearing the completion of the Phase II clinical trial for the XTMAB project, with further announcements expected soon [1] Summary by Categories - **Clinical Trial Progress** - The Phase II clinical trial for the XTMAB project is approaching its conclusion [1]

Core Points - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has received ANDA approval from the U.S. FDA for its Propofol Emulsion Injection in three specifications: 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL [1][2][3] - The reference formulation for Propofol Emulsion Injection is held by Fresenius Kabi USA LLC, which was approved by the U.S. FDA in June 1996 under the brand name DIPRIVAN [2] - Currently, there are eight other manufacturers in the U.S. that have approved generic versions of Propofol Emulsion Injection [2] - The company has invested approximately RMB 73.66 million in the research and development of the Propofol Emulsion Injection project [2] - The newly approved product is expected to be launched in the U.S. soon, which is anticipated to have a positive impact on the company's operating performance [2] Drug Information - Drug Name: Propofol Emulsion Injection [3] - Indication: General anesthesia and sedation [3] - Dosage Form: Injection [3] - Specifications: 200 mg/20 mL, 500 mg/50 mL, 1,000 mg/100 mL [3] - ANDA Number: 217945 [3] - Applicant: Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [3]

Policy Developments - The National Healthcare Security Administration announced five typical cases of fraud involving maternity insurance funds, urging insured units and individuals to participate legally and provide accurate application materials to safeguard the fund [1] Drug and Device Approvals - Dongcheng Pharmaceutical's subsidiary received a production license for radioactive drugs, with expectations that it will not significantly impact current performance until commercial production is approved [1] - Jianyou Co., Ltd. received FDA approval for its propofol emulsion injection, with an investment of approximately RMB 73.66 million in R&D, and plans to launch the product in the U.S. soon [2] - Aihong Pharmaceutical presented clinical trial data for APL-1401 at the European Colorectal Congress, focusing on treating moderate to severe ulcerative colitis [6] - Fosun Pharma's subsidiary received approval for clinical trials of FXS887, an innovative drug for treating advanced malignant solid tumors [7] - Xinlitai received approval for clinical trials of SAL0140, a novel drug for chronic kidney disease, which could provide new treatment options if successful [8] Capital Market Activities - Lexin Medical announced that its controlling shareholder, Pan Weichao, has released the pledge on 18.71 million shares, which is 28.01% of his holdings and 8.56% of the total share capital [3] - Berry Genomics reported a decrease in the shareholding ratio of its controlling shareholder, Gao Yang, to 6.90% due to stock pledge defaults, with no significant adverse impact on the company's operations [4] - Tailong Pharmaceutical is planning a major matter that may lead to a change in control, with stock suspension expected to last no more than three trading days [5] Strategic Collaborations - JD Health and Boehringer Ingelheim Animal Health signed a strategic cooperation agreement to enhance the quality development of the domestic pet health industry through resource integration and complementary advantages [10] Regulatory Actions - Guizhou Bai Ling's actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading and other violations, which does not affect the company's daily operations [11]